Comparative Pharmacology
Head-to-head clinical analysis: FLORONE E versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLORONE E versus FLUDROCORTISONE ACETATE.
FLORONE E vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLORONE E contains diflorasone diacetate, a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and reducing prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Apply a thin film to affected skin area twice daily. Not for ophthalmic, oral, or intravaginal use.
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Approximately 2-4 hours (terminal) for the active moiety diflorasone; clinically, this supports twice-daily dosing for chronic skin conditions.
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Primarily renal (<1% unchanged as metabolite) and biliary, with <1% excreted unchanged in urine. The remainder is metabolized and excreted in feces via bile.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid